Your browser doesn't support javascript.
loading
Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non-Cirrhotic Patients: A Societal Perspective.
Elsisi, Gihan Hamdy; Aburawash, Asmaa; Waked, Emam.
Afiliação
  • Elsisi GH; Pharmacoeconomic Unit, Central Administration for Pharmaceutical Affairs, Ministry of Health, Cairo, Egypt. Electronic address: gihanhamdyelsisi@hotmail.com.
  • Aburawash A; Pharmacoeconomic Unit, Central Administration for Pharmaceutical Affairs, Ministry of Health, Cairo, Egypt.
  • Waked E; National Liver Institute, Menoufiya, Egypt.
Value Health Reg Issues ; 13: 7-15, 2017 Sep.
Article em En | MEDLINE | ID: mdl-29073993
OBJECTIVES: To evaluate the cost-effectiveness of sofosbuvir (SOF) + ribavirin (RBV), SOF + daclatasvir (DCV), and SOF + ledipasvir (LDV) + RBV compared with SOF + pegylated interferon alfa (pegIFN) + RBV in the treatment of patients infected with hepatitis C virus in Egypt. METHODS: Two Markov models were developed on the basis of the Egyptian clinical data and practice and were derived from published sources. The clinical parameters were derived from two sources: the Egypt multicenter national treatment program and previously published randomized clinical trials. The utility of the health states was derived using the available published data. Direct medical costs were obtained from the National Liver Institute database. RESULTS: In noncirrhotic patients, incremental cost-effectiveness ratios of US $2330 per quality-adjusted life-year (QALY) gained for the SOF + LDV + RBV, -US $9043/QALY for the SOF + DCV, and -US $1332/QALY for the SOF + RBV regimens were yielded. In cirrhotic patients, incremental cost-effectiveness ratios of -US $4170/QALY gained for the SOF + LDV + RBV, -US $9515/QALY for the SOF + DCV, and -US $2289/QALY for the SOF + RBV regimens were yielded. The SOF + DCV regimen was the most cost-saving option for cirrhotic and noncirrhotic patients. Deterministic sensitivity analyses remain robust. CONCLUSIONS: The present study concludes that the SOF + DCV regimen among other currently available regimens is the most cost-saving option that yields the most favorable future health economic outcomes compared with the SOF + pegIFN + RBV regimen across a broad spectrum of patients, including those with cirrhosis.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 Base de dados: MEDLINE Assunto principal: Antivirais / Análise Custo-Benefício / Hepatite C Crônica Tipo de estudo: Clinical_trials / Health_economic_evaluation Aspecto: Patient_preference Limite: Humans País/Região como assunto: Africa Idioma: En Revista: Value Health Reg Issues Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 Base de dados: MEDLINE Assunto principal: Antivirais / Análise Custo-Benefício / Hepatite C Crônica Tipo de estudo: Clinical_trials / Health_economic_evaluation Aspecto: Patient_preference Limite: Humans País/Região como assunto: Africa Idioma: En Revista: Value Health Reg Issues Ano de publicação: 2017 Tipo de documento: Article